Calgary

PACE-calgary-group-shot.jpg
 

Calgary Centre: University of Calgary

Area of Focus: Reducing Chronic Steroid Use

  • Chronic steroid use is too high. Three quarters of Crohn’s disease and ulcerative colitis patients referred to an IBD specialist are on chronic steroid therapy.
  • In the last three years the clinic has tested three new agents, which have been approved for the treatment of IBD as alternatives to chronic steroid therapy.
  • The centre will continue to develop therapies that will improve patients’ quality of life and allow for expanded choices.

rsz_pace-social-postcard-tammy.jpg

Timeline

  • This project has secured funding for the next four years, with the goal of continuing well beyond 2020. The University of Calgary centre will participate in quarterly reports with all centres under the leadership of Crohn’s and Colitis Canada.
  • The University of Calgary centre will focus on reducing chronic steroid use for the next two years and will then begin adopting the specialties of the other centres in years three and four.

rsz_pace-social-postcard-rob-maver.jpg

Leadership: Remo Panaccione, MD, FRCPC

  • Associate Professor, Department of Medicine, University of Calgary, Cumming School of Medicine, Snyder Institute for Chronic Diseases; Director, Inflammatory Bowel Disease Clinic; Director, Gastroenterology Training Program.
  • Panaccione is an internationally recognized expert in IBD.
  • His special interest lies in the implementation and performance of clinical trials of new IBD therapies. He also performs research in identifying new targets to develop new therapies.

rsz_pace-social-postcard-panaccione.jpg

PACE Centre: University of Calgary IBD Clinic

  • Over the past 15 years an accomplished team of University of Calgary and Alberta Health Services research clinicians have established Calgary as one of the top three IBD centres in the world.
  • The U of C IBD clinic has produced over 600 scientific publications and is ranked fifth in the world for academic output.
  • In 2009 the Alberta IBD Consortium (AIBDC) was created through a $5 million grant from Alberta Innovates Health Solutions. It links the research expertise of the University of Calgary and the University of Alberta.
  • The centre currently supports basic science, including immunology, microbiology, genetics, and bioinformatics, as well as clinical research which includes clinical and non-clinical trials, translational research, environmental health, and population and health promotion research.

Read the News Release here

Questions? Contact: Natasha Kachan

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 150 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest